



EXPANDED PROGRAMME ON IMMUNIZATION

LIST OF ARTICLES IN THE WEEKLY EPIDEMIOLOGICAL RECORD, 1977-1988*

<u>WER NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
3	GLOBAL ADVISORY GROUP	9-13
4	AMRO: TECHNICAL ADVISORY GROUP ON POLIOMYELITIS	17-20
6	IRAQ: PROGRAMME ACCELERATION	33-36
9	NEPAL: COLD CHAIN EVALUATION	60-62
10	ZAMBIA: CDD-EPI JOINT PROGRAMME SURVEYS	65-68
12	EURO: REPORTED TRENDS OF EPI DISEASES	81-85
14	EURO: SECOND MEETING OF THE EUROPEAN ADVISORY GROUP	97-101
16	UGANDA: PROGRAMME REVIEW	114-117
18	IRAQ: IMPACT OF PROGRAMME ACCELERATION ON DISEASE INCIDENCE	130-132
21	PHILIPPINES: LOCAL AREA MONITORING	157-160
22	GLOBAL ERADICATION OF POLIOMYELITIS BY THE YEAR 2000	161-162
22	NORWAY: MEASLES ELIMINATION BY 1990	163-164
25	TURKEY: PROGRAMME REVIEW	185-188
26	INDIA: COLD CHAIN EVALUATION	193-196
29	CHINA: IMMUNIZATION COVERAGE AND DISEASE INCIDENCE	220-221
30	CHINA: DIPHTHERIA AND MEASLES CONTROL	225-227
33	INDIA: POLIOMYELITIS SURVEILLANCE AND VACCINE EFFICACY	249-251

* This document replaces document WHO/EPI/GEN/86.1, Rev. 1

This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means - electronic, mechanical or other without the prior written permission of WHO.

The views expressed in documents by named authors are solely the responsibility of those authors.

Ce document n'est pas destiné à être distribué au grand public et tous les droits y afférents sont réservés par l'Organisation mondiale de la Santé (OMS). Il ne peut être commenté, résumé, cité, reproduit ou traduit, partiellement ou en totalité, sans une autorisation préalable écrite de l'OMS. Aucune partie ne doit être chargée dans un système de recherche documentaire ou diffusée sous quelque forme ou par quelque moyen que ce soit - électronique, mécanique, ou autre - sans une autorisation préalable écrite de l'OMS.

Les opinions exprimées dans les documents par des auteurs cités nommément n'engagent que lesdits auteurs.

(1988 continued)

34	UNITED KINGDOM: TETANUS SURVEILLANCE	258-259
37	EURO: CONTRAINDICATIONS FOR VACCINES USED IN EPI	279-281
38	IRAN: POLIOMYELITIS LAMENESS SURVEY	285-286
40	INDONESIA: IMPACT OF TETANUS TOXOID IMMUNIZATION	301-302
43	ISRAEL: POLIOMYELITIS OUTBREAK	325-326
43	BURMA: PROGRAMME REVIEW	326-327
45	COMOROS: MISSED OPPORTUNITIES FOR IMMUNIZATION	344-346
46	POLAND: HEAT STABILITY OF ORAL POLIO AND MEASLES VACCINES	349-352
50	MOZAMBIQUE: LYMPHADENITIS ASSOCIATED WITH BCG IMMUNIZATION	381-383
51	UNITED KINGDOM: IMMUNIZATION POLICY: MEASLES/ MUMPS/RUBELLA VACCINE IMPLEMENTATION	392-394

<u>WER NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
3	GLOBAL ADVISORY GROUP	5-9
4	UNITED KINGDOM: MEASLES: AN UNNECESSARY EPIDEMIC IN 1986	15-17
5	INDIA: LOCAL AREA MONITORING	25-27
7	IRAN: NEONATAL TETANUS MORTALITY SURVEYS	38-40
9	THE RISK OF TRANSMITTING HIV INFECTION THROUGH IMMUNIZATION	53-54
10	MONGOLIA: IMMUNIZATION COVERAGE	61-62
10	PANAMA: MEASLES	62-64
13	INDONESIA: PROGRAMME REVIEW	87-90
14	MAURITANIA: COST-EFFECTIVENESS STUDY	95-97
16	JORDAN: PROGRAMME REVIEW	110-112
18	POLAND: IMMUNIZATION COVERAGE SURVEY TO VALIDATE DATA FROM THE ROUTINE REPORTING SYSTEM	129-131
19	JOINT WHO/UNICEF STATEMENT ON VITAMIN A FOR MEASLES	133-134
20	CHINA: CONTRACT SYSTEM TESTED	142-143
21	USSR: PERTUSSIS INCIDENCE AND IMMUNIZATION COVERAGE	149-151
24	SYRIA: PROGRAMME ACCELERATION	173-175
25	AUSTRIA: IMMUNIZATION COVERAGE SURVEY	183-185
29	INDONESIA: IMMUNIZATION COVERAGE SURVEY METHODOLOGY STUDIES	213-216
30	USA: NOSOCOMIAL MEASLES AND MISSED OPPORTUNITIES	223-224
33	GLOBAL STATUS REPORT	241-243

1987 (continued)

34	TANZANIA: LOCAL AREA MONITORING	252-254
35	BANGLADESH: NEONATAL TETANUS AND BIRTH ORDER	262
38	THAILAND: PROGRAMME REVIEW	283-285
39	FRANCE: SUDDEN INFANT DEATH AND DPT/IPV IMMUNIZATION: A CASE-CONTROL STUDY	293-294
40	HIV AND CHILDHOOD IMMUNIZATION	297-299
41	NEONATAL TETANUS IN AFRICA	305-308
42	RWANDA: MEASLES IMMUNIZATION OF ILL CHILDREN	313-315
43	TURKEY: LOCAL AREA MONITORING	325-327
44	EGYPT: NEONATAL TETANUS MORTALITY SURVEYS	332-335
45	BANGLADESH: LOCAL AREA MONITORING	341-342
46	CHANGING NEEDLES BUT NOT THE SYRINGE: AN UNSAFE PRACTICE	345 346
47	BANGLADESH: NEONATAL TETANUS MORTALITY SURVEY	356-357
50	TETANUS CONTROL	380-383
51	BELIZE: PROGRAMME ACCELERATION	385-386

1986

<u>WER</u> <u>NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
3	GLOBAL ADVISORY GROUP (1985)	13-16
4	BHUTAN: PROGRAMME REVIEW	21-23
6	CHOICE OF SYRINGES FOR THE EPI	41-43
7	SAUDI ARABIA: DISEASE INCIDENCE AND IMMUNIZATION COVERAGE	45-46
10	NETHERLANDS: PERTUSSIS VACCINE EFFICACY	73-74
11	MAURITIUS: EXPANDED PROGRAMME ON IMMUNIZATION AS A COMPONENT OF PRIMARY HEALTH CARE, PROGRAMME REVIEW	77-79
12	BANGLADESH: PUBLIC HEALTH IMPORTANCE OF MEASLES	89-90
14	INDONESIA: NEONATAL TETANUS MORTALITY SURVEYS	101-102
16	KENYA: NEONATAL TETANUS MORTALITY SURVEYS.	117-118
17	BHUTAN: MISSED OPPORTUNITIES FOR MEASLES IMMUNIZATION	128-129

1986 (continued)

19	PAKISTAN: PROGRAMME IMPACT	142-145
20	FRANCE: EVALUATION OF A MEASLES-RUBELLA IMMUNIZATION PROGRAMME	151-153
21	INDONESIA : SILICA GEL AS A TRANSPORT MEDIUM FOR CORYNEBACTERIUM DIPHTHERIAE	159-160
22	SINGAPORE MEASLES CONTROL	165-168
23	GLOBAL: REPORTED PERTUSSIS INCIDENCE	174-176
24	SWEDEN: DISEASE INCIDENCE 1950-1954	184-186
25	MALAWI: MEASLES SURVEILLANCE METHODOLOGY	191-193
28	GLOBAL: EFFICACY OF INFANT BCG IMMUNIZATION	216-218
29	USSR: IMPACT OF IMMUNIZATION PROGRAMME	221-222
30	LESOTHO: PROGRAMME REVIEW	233-234
33	CANADA: TRENDS IN MEASLES	252-254
35	FRANCE: SUDDEN INFANT DEATH AND DPT/IPV IMMUNIZATION	265-266
36	INDIA: PROGRAMME ACCELERATION	276-277
37	SOMALIA: PROGRAMME ACCELERATION	282-284
40	GLOBAL: FIBREGLASS WICKS	308-309
41	GUINEA: PROGRAMME REVIEW	315-316
42	FRANCE: IMMUNIZATION COVERAGE SURVEY	324-325
43	SRI LANKA: PROGRAMME REVIEW	329-331
44	IVORY COAST: NOSOCOMIAL MEASLES	338-340
45	POLAND: TETANUS SURVEILLANCE	349-350
46	POLAND: MEASLES VACCINE EFFICACY	356-357
47	ECONOMIC EVALUATION	365-366
48	COLOMBIA: PROGRAMME ACCELERATION	372-373
49	AFGHANISTAN: PROGRAMME ACCELERATION	382

1985

<u>WER NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
2	RWANDA: PROGRAMME EVALUATION	7-9
3	GLOBAL ADVISORY GROUP (1984)	13-16
8	ZAMBIA: PROGRAMME REVIEW	56-58
10	IVORY COAST, CAMEROON, GAMBIA: CONTROL OF POLIOMYELITIS	69-71
11	THAILAND: MEASLES OUTBREAK AMONG HILL TRIBES	79
13	SRI LANKA: PUBLIC HEALTH IMPORTANCE OF MEASLES	95-97
14	BURMA: PUBLIC HEALTH IMPORTANCE OF MEASLES	103-105
16	IRAN: PROGRAMME REVIEW	119-121
18	FIELD EVALUATION OF VACCINE EFFICACY	133-136
19	THAILAND: PROGRAMME IMPACT: DECREASING MORBIDITY IN BANGKOK	141-144
21	BRAZIL: INVESTIGATION OF A MEASLES OUTBREAK	157-160
22	EUROPEAN CONFERENCE ON IMMUNIZATION POLICIES	165-168
25	SRI LANKA: ECONOMIC APPRAISAL	191-194
27	ZIMBABWE: EVALUATION OF IMMUNIZATION COVERAGE	209-210
29	BANGLADESH: NEONATAL TETANUS CONTROL	224-225
31	INDIA: MISSED IMMUNIZATION OPPORTUNITIES	237-238
33	PAKISTAN: PROGRAMME REVIEW	253-256
34	GLOBAL STATUS REPORT	261-263
37	REAPPRAISAL OF EARLY OPV AND DPT IMMUNIZATION	284-286
39	YUGOSLAVIA: HEAT STABILITY OF PERTUSSIS VACCINE	300-301
41	JORDAN: NEONATAL TETANUS MORTALITY AND POLIOMYELITIS LAMENESS SURVEYS	318-320
45	VENEZUELA: PROGRAMME REVIEW	346-349
46	INDONESIA: CONTROL OF NEONATAL TETANUS	353-354
47	SURINAME: IMMUNIZATION COVERAGE	366-367
49	BURMA: NEONATAL TETANUS MORTALITY SURVEY	377-380
51	AMR: GOAL FOR 1990: ERADICATION OF POLIOMYELITIS IN THE AMERICAS	394-395

1984

<u>WER NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
3	INDICATIONS AND CONTRAINDICATIONS FOR VACCINES USED IN THE EPI	13-15
4	INDONESIA: OUTBREAK OF WHOOPING COUGH	26-27
6	SUDAN POLIOMYELITIS PREVALENCE SURVEYS	42
7	KENYA: INFLUENCE OF MALARIA ON THE IMMUNE RESPONSE TO TETANUS TOXOID IN PREGNANCY	45-46
9	ICE LINED REFRIGERATORS	63-64
11	ECUADOR: PROGRAMME REVIEW	77-79
12	GLOBAL ADVISORY GROUP (1983)	85-89
14	INDIA: POLIOMYELITIS SURVEILLANCE AND VACCINE/EFFICACY	101-104
16	CAMEROON: COMMUNITY PARTICIPATION AND IMMUNIZATION COVERAGE	117-119
17	IVORY COAST: MEASLES VACCINE EFFICACY	127-128
19	EUROPE: FEASIBILITY OF ELIMINATION OF VACCINE-PREVENTABLE DISEASES	143-145
21	TUNISIA: COLD CHAIN EVALUATION	157-160
22	NEW ZEALAND: EFFICACY OF PERTUSSIS VACCINE	169-170
24	IRAN: DEVELOPMENT OF POLIO ANTIBODIES IN A RURAL AREA	185-187
25	PHILIPPINES: PROGRAMME REVIEW	192-194
26	USA: CONTRAINDICATIONS TO PERTUSSIS	199-201
32	YUGOSLAVIA: CHANGES IN TETANUS MORBIDITY	247-249
36	BURMA: PROGRAMME REVIEW	273-276
38	INDONESIA: DIPHTHERIA IMMUNIZATION AND MORBIDITY	293-295
39	COMPUTER SIMULATION OF THE EPI SURVEY METHODOLOGY	297-300
41	SRI LANKA: TETANUS SURVEILLANCE	319
44	PAKISTAN: MISSED IMMUNIZATION OPPORTUNITIES	341-342
45	MALAWI: PROGRAMME REVIEW	346-347
46	BANGLADESH: POLIOMYELITIS PREVALENCE SURVEY	353-354
48	CHINA: IMMUNIZATION OF NEONATES WITH TRIVALENT ORAL LIVE POLIO VIRUS VACCINE	369-371

1983

<u>WER NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
1	KUWAIT: IMMUNIZATION COVERAGE	1-4
3	GLOBAL ADVISORY GROUP (1982)	13-18
4	LESOTHO: PROGRAMME REVIEW	25-26
5	CAMEROON, SICK CHILDREN: TARGETS FOR IMMUNIZATION	29-30
7	ZIMBABWE: COVERAGE EVALUATION	45-47
8	INDONESIA: NEONATAL TETANUS SURVEY	56-57
9	GERMAN DEMOCRATIC REPUBLIC: ADVERSE REACTIONS TO IMMUNIZATION	62-64
10	IVORY COAST: NEONATAL TETANUS SURVEY	71-72
11	HUNGARY: DISEASE INCIDENCE AND IMMUNIZATION COVERAGE	77-80
13	BANGLADESH: IMPACT OF TRAINED TRADITIONAL BIRTH ATTENDANTS AND TETANUS TOXOID ON NEONATAL MORTALITY	93-94
15	YEMEN ARAB REPUBLIC: PROGRAMME REVIEW	112-113
17	TUNISIA: EVALUATION OF IMMUNIZATION COVERAGE AND MORBIDITY AND MORTALITY FROM DIARRHOEAL DISEASES	125-127
18	GAMBIA: MEASLES MORTALITY AND VACCINE EFFICACY	133-135
22	USA: REACTIONS TO DPT IMMUNIZATIONS	170-171
23	GLOBAL STATUS REPORT	173-176
25	KENYA: COST ANALYSIS	193-195
29	CAMEROON: COST ANALYSIS	221-226
30	CONGO: COVERAGE EVALUATION	231
31	COST OF COLD CHAIN EQUIPMENT	237-240
32	BRAZIL: POLIOMYELITIS CONTROL	247-248
34	MOROCCO: DISEASE INCIDENCE AND IMMUNIZATION COVERAGE	259-260
35	CONGO: POLIOMYELITIS PREVALENCE SURVEY	267
36	DEMOCRATIC YEMEN: POLIOMYELITIS PREVALENCE SURVEY	273-274
37	EPI IN THE REGION OF THE AMERICAS	281-284
39	COUNTRY OPERATIONS IN THE ENGLISH-SPEAKING CARIBBEAN	297-299

1983 (continued)

40	INDONESIA: IMMUNIZATION OF SICK CHILDREN	309-310
42	MALAWI: NEONATAL TETANUS MORTALITY SURVEY	326-327
44	SOMALIA: POLIOMYELITIS PREVALENCE SURVEY	341-342
45	INTERNATIONAL SYMPOSIUM ON POLIOMYELITIS CONTROL	349-350
46	COLUMBIA: FREEZING ICEPACKS	354-355
47	BOTSWANA: PROGRAMME REVIEW	361-363
51	BURUNDI: PROGRAMME EVALUATION	393-395

1982

<u>WER</u> <u>NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
1	NIGER: POLIOMYELITIS PREVALENCE SURVEY	4
2	YEMEN: VACCINE COLD CHAIN MANAGEMENT INDICATORS	12-14
2	NIGERIA: POLIOMYELITIS PREVALENCE SURVEY	14
4	COLUMBIA: MULTIDISCIPLINARY EVALUATION	26-29
6	CANADA: IMMUNIZATION STATUS OF CHILDREN ENTERING SCHOOL	46-47
7	PANAMA: COVERAGE EVALUATION	51-54
8	BOLIVIA: MULTIDISCIPLINARY EVALUATION	59-63
11	IVORY COAST: EVALUATION OF IMMUNIZATION COVERAGE	85-86
12	KENYA: THE OPTIMAL AGE FOR MEASLES IMMUNIZATION	89-91
13	CHINA: PROGRAMME DESCRIPTION AND COVERAGE	97-99
15	SRI LANKA: PROGRAMME REVIEW	117-118
17	CLUSTER SAMPLING TO ASSESS IMMUNIZATION COVERAGE	129-131
18	PREVENTION OF NEONATAL TETANUS	137-142
20	CAMEROON: IMMUNIZATION COVERAGE AND POLIOMYELITIS	158-160
21	CONGO: FIELD TRIALS ON AN ICE-LINED REFRIGERATOR	161-163
22	IVORY COAST: COST-EFFECTIVENESS	170-173
23	YEMEN: IMPACT OF TELEVISION CAMPAIGN	177-178
24	ALGERIA: ROUTINE IMMUNIZATIONS FOR PRE-SCHOOL AGE CHILDREN	186-187

1982 (Continued)

25	CANADA: REACTIONS TO TETANUS TOXOID	193-194
26	YEMEN: MEASLES SEROPOSITIVITY IN CHILDREN	198-199
27	SUDAN: NEONATAL TETANUS MORTALITY	205-207
29	SINGAPORE: DISEASE INCIDENCE AND IMMUNIZATION COVERAGE	221-222
32	SRI LANKA: EVALUATION OF IMMUNIZATION COVERAGE	241-242
33	GLOBAL FIVE-POINT ACTION PROGRAMME	249-250
35	SYRIA: PROGRAMME DEVELOPMENT AND EVALUATION	266-267
38	GAMBIA: COST STUDY	292-294
39	THAILAND: IMPROVEMENT OF COVERAGE	301-302
44	JORDAN: PROGRAMME REVIEW	337-339
45	PARALYSIS ASSOCIATED WITH POLIOMYELITIS VACCINE	345-348
46	CUBA: PROGRAMME EVALUATION	355-357
47	USE OF SURVEY DATA TO SUPPLEMENT DISEASE SURVEILLANCE	361-362
48	MADAGASCAR: POLIOMYELITIS PREVALENCE SURVEY	376-377
49	THAILAND: PROGRAMME REVIEW	385-387
50	INDONESIA: NEONATAL TETANUS SURVEY	395
51	GAMBIA: INTERVIEW	398

1981

<u>WER</u> <u>NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
2	GLOBAL ADVISORY GROUP (1980)	9-15
6	MALAYSIA (PENINSULAR): PROGRAMME IMPACT	43-46
7	USA: MEASLES VACCINE EFFICACY	53-55
10	COUNTRY OPERATIONS IN THE ENGLISH-SPEAKING CARIBBEAN, 1979	74-77
11	GRAPHIC MONITORING OF IMMUNIZATION COVERAGE	85-86
11	NEPAL: SURVEY OF NEONATAL TETANUS	87
12	BURMA: EVALUATION OF IMMUNIZATION COVERAGE	89-90
13	INDONESIA: AN ECONOMIC APPRAISAL	99-101

1981 (continued)

14	INDIA: TRAINING ACTIVITIES	109-110
15	PAPUA NEW GUINEA: EVALUATION OF IMMUNIZATION COVERAGE	114
17	INDIA: POLIOMYELITIS PREVALENCE SURVEYS, TAMIL NADU	131-132
18	GLOBAL STATUS REPORT	137-140
19	UNITED KINGDOM: THE RELATIONSHIP BETWEEN THE INCIDENCE OF SOME EPI DISEASES AND IMMUNIZATION COVERAGE LEVELS	150-151
20	EPI IN THE EASTERN MEDITERRANEAN REGION	153-155
23	STABILITY OF FREEZE-DRIED MEASLES VACCINE	177-179
24	BANGLADESH: REDUCTION OF NEONATAL DEATHS BY IMMUNIZING WOMEN AGAINST TETANUS	185-186
27	BANGLADESH: ACCEPTANCE OF TETANUS TOXOID IMMUNIZATION AMONG PREGNANT WOMEN	209-210
28	YEMEN: PROGRAMME DEVELOPMENT	217-220
28	KENYA: EVALUATION OF IMMUNIZATION COVERAGE	220-221
29	INDONESIA: EVALUATION OF IMMUNIZATION COVERAGE	227-228
30	TANZANIA: SEROCONVERSION AFTER MEASLES IMMUNIZATION	234-237
31	GABON: COVERAGE EVALUATION	245
32	RWANDA: EVALUATION OF IMMUNIZATION COVERAGE	253-254
33	MOROCCO: EVALUATION OF IMMUNIZATION COVERAGE, INCIDENCE OF DIARRHOEA AND OF MORTALITY PRECEDED BY DIARRHOEA	262-263
35	GAMBIA: PROGRAMME EVALUATION	276-278
36	POLAND: DISEASE INCIDENCE AND IMMUNIZATION COVERAGE, 1950-1980	281-284
38	YEMEN: POLIOMYELITIS PREVALENCE SURVEY	297-298
40	AUSTRALIA: POLIOMYELITIS AND DPT IMMUNIZATION COVERAGE	313-314
42	CHINA: MEASLES CONTROL PROGRAMME	332-333
43	IVORY COAST: DEVELOPMENT OF THE PROGRAMME, 1978-1980	341-343
44	THAILAND: PROGRAMME IMPACT ON DISEASE INCIDENCE	351
45	MAINTAINING AND IMPROVING THE COLD CHAIN	355-358
46	BAHRAIN: PROGRAMME REVIEW	362-364
46	CANADA: COMPULSORY IMMUNIZATION LAW	367-368
47	NETHERLANDS: THE INCIDENCE OF 5 VACCINE PREVENTABLE DISEASES AND IMMUNIZATION COVERAGE	369-372
48	PHILIPPINES: POLIOMYELITIS PREVALENCE SURVEYS	377-378
50	CAMEROON: POLIOMYELITIS PREVALENCE SURVEYS	397

1980

<u>WER</u> <u>NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
1	BCG IN INFANTS	1-3
2	GLOBAL ADVISORY GROUP (1979)	9-11
4	CANADA: REPORT OF CHILDHOOD IMMUNIZATION STATUS	25-28
5	CAMEROON: INJECTIONS AND PARALYTIC POLIOMYELITIS	38-39
7	BANGLADESH: NEONATAL TETANUS PREVENTION	50-52
8	CHINA: MEASLES SEROLOGY	57-58
8	MALAWI: POLIOMYELITIS PREVALENCE SURVEY	60-61
9	TURKEY: COVERAGE EVALUATION AND PROGRAM IMPACT	66-67
12	SOMALIA: MEASLES EPIDEMIOLOGY	85-87
14	ALGERIA PROGRAMME IMPACT	100-101
18	THAILAND: COVERAGE EVALUATION	132-133
20	BRAZIL: IMMUNIZATION REPORT	145-147
21	GLOBAL STATUS REPORT	153-157
24	CONGO: COVERAGE EVALUATION	177-179
32	INDIA: COVERAGE EVALUATION	244-245
33	HEAT STABILITY OF VACCINES	252-254
35	NIGERIA: PROGRAMME DESCRIPTION, 1975-1979, OYO STATE	265-267
37	PROGRAMME COSTING GUIDELINES	281-283
38	THAILAND: AN ECONOMIC APPRAISAL	289-292
39	ZAIRE: COVERAGE EVALUATION	297-300
41	AMR: TRAINING ACTIVITIES	316
42	BOTSWANA: COVERAGE EVALUATION	321-323
43	SRI LANKA: COVERAGE EVALUATION	329-330
45	BOTSWANA: MEASLES SURVEILLANCE	351-352
46	USA: IMMUNIZATION LEVELS IN SCHOOL CHILDREN	353-354
50	EFFECTS OF FREEZING ON DPT VACCINES	385-390
51	EFFECTS OF FREEZING ON DPT VACCINES (continued)	396-398
52	IVORY COAST: POLIOMYELITIS PREVALENCE SURVEY	401-403

1979

<u>WER NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
10	INDONESIA: MEASLES EPIDEMIOLOGY	73-76
12	ROLE OF PUBLIC HEALTH LABORATORIES IN POLIOMYELITIS CONTROL	90-93
13	GABON: IMMUNIZATION REPORT	97-98
19	BRAZIL: IMMUNIZATION REPORT	145
23	INDONESIA: POLIOMYELITIS EPIDEMIOLOGY	177-178
25	ALGERIA: COVERAGE EVALUATION	193-194
26	THAILAND: POLIOMYELITIS PREVALENCE SURVEY	202-203
27	CANADA: IMMUNIZATION RATES AND VACCINE FAILURES	210-211
29	IVORY COAST: COVERAGE EVALUATION	221-223
35	PAPUA NEW GUINEA: COVERAGE EVALUATION	265-266
42	CAMEROON: OPV SEROCONVERSION	324
44	KENYA: MEASLES IMMUNIZATION	337-339
45	INDIA: MEASLES SURVEILLANCE	345
46	IMPROVED STABILITY OF MEASLES VACCINE	354
49	COSTA RICA: PROGRAMME IMPACT	377-379
584	PAPUA NEW GUINEA: COVERAGE EVALUATION	385-386
50	INTERVALS BETWEEN SUCCESSIVE DOSES OF KILLED VACCINES	388-389

1978

<u>WER NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
3	SRI LANKA: IMMUNIZATION REPORT	21-22
7	TANZANIA: PROGRAMME REPORT	45
18	CANADA: FOLLOW-UP ON IMMUNIZATION STATUS	131
19	CAMEROON: IMMUNIZATION COVERAGE, REASONS FOR NON-ATTENDANCE, MEASLES AND POLIOMYELITIS SURVEILLANCE	133-135
20	PHILIPPINES: FIELD STUDIES: MEASLES, POLIOMYELITIS, PERTUSSIS	144-146
21	SRI LANKA: POLIOMYELITIS SURVEILLANCE	149-150

1978 (continued)

22	BRAZIL: IMMUNIZATION REPORT	159
24	BARBADOS: DIPHTHERIA SURVEILLANCE	173-175
28	INDONESIA: COVERAGE EVALUATION	205
33	UNITED KINGDOM: MEASLES SURVEILLANCE	245
36	BANGLADESH: NEONATAL TETANUS SURVEY	269-270
37	EGYPT: PROGRAMME EVALUATION	278-279
42	CANADA: DIPHTHERIA SURVEILLANCE	301-302

1977

<u>WER</u> <u>NO.</u>	<u>SUBJECT</u>	<u>PAGES</u>
7	GLOBAL: EPI - PROGRAMME DESCRIPTION	74-75
10	KENYA: PROGRAMME EVALUATION	93-94
13	VACCINES: PRODUCTION, SUPPLY AND CONTROL	117-119
13	FREEZING AND THAWING OF OPV AND MEASLES VACCINES	119
17	BURMA: OBJECTIVES AND STRATEGY	145-146
20	INDONESIA: NATIONAL PROGRAMME AND EVALUATION	169-171
24	KENYA: EVALUATION OF MOBILE TEAMS	197-199
27	CANADA: TRENDS IN VACCINE PREVENTABLE DISEASES, 1957-1976.	224-225
29	KENYA: FIXED HEALTH UNITS AND IMMUNIZATION	237-239
33	EGYPT: POLIOMYELITIS PREVALENCE SURVEY	269-271
38	CAMEROON: COVERAGE EVALUATION	301-303
43	DOMINICAN REPUBLIC: POLIOMYELITIS IMMUNIZATION CAMPAIGN	341-342
43	CANADA: PROMOTION OF IMMUNIZATION	347
47	NIGERIA: MEASLES OUTBREAK	373-374

EPI ARTICLES IN THE WER BY MAJOR SUBJECT, BY YEAR AND ISSUE NUMBER: 1977-1984

Major Subject	1977	1978	1979	1980	1981	1982	1983	1984
PROGRAMME ASPECTS:								
- Acceleration	-	-	-	-	-	-	-	-
- Description & Planning of the Programme	7, 17, 20	-	-	-	-	-	-	-
- GAG Reports	-	-	-	2	2	-	3	12
- Global and Regional Status Reports	-	-	-	21	10, 18, 20	33	23, 37, 39	-
- Coverage surveys	38	3, 19, 22, 28	13, 19, 25, 27	4, 18, 20, 24, 32	12, 15, 28, 29	6, 7, 11, 17, 24, 32	1, 7, 17, 30	-
- Country Programme Reviews	10	7, 37	29, 35, 50	39, 42, 43, 46	31, 32, 33, 40	4, 8, 15, 35, 44, 49	4, 15, 47, 51/52	11, 25, 36, 45
- and Development Reports	27	-	49	14	6, 19, 36, 44, 47	13, 20, 29, 46	11, 34	-
- Disease Impact	-	-	-	-	45	2, 21	31, 46	9, 21
- Cold Chain	-	-	-	-	-	23, 39	-	16
- Public Participation	43	-	-	41	14	-	-	-
- Training	-	-	-	37, 38	13	22, 38	25, 29	-
- Cost Issues	-	-	-	-	11, 46	47	-	-
- Other Operational Issues	24, 29	18	-	-	-	-	-	-
EPIDEMIOLOGICAL ASPECTS:								
- of Diphtheria	-	24, 42	-	-	-	-	-	-
- of Pertussis	-	36	-	-	11	27, 50	8, 10, 42	32, 41
- of Tetanus	47	33	10, 45	8, 12, 45	-	26, 51/52	-	-
- of Measles	33	21	12, 23, 26	8, 52	17, 38, 48, 50	1, 2, 48	35, 36, 44	6, 14, 24, 46
- of Poliomyelitis	-	-	-	-	-	-	-	-
- of Tuberculosis	-	20	-	-	-	-	-	-
- General	-	-	-	-	-	-	-	-
VACCINES:								
- Diphtheria	-	-	-	-	24, 27	-	-	38
- Tetanus	-	-	-	7	-	18, 25	13	7
- Pertussis	-	-	-	-	-	-	-	4, 22
- Measles	-	-	44	-	7, 30, 42	12	18	17
- Polio	43	-	42	5	-	45	32, 45	48
- BCG	-	-	-	1	-	-	-	-
- General (including vaccine stability)	13, 13	-	46, 50	33, 50, 51	23	-	-	19, 39
- Contraindications	-	-	-	-	-	-	5, 9, 22, 40	3, 26, 44
Total, by year	14	13	17	28	37	35	32	25
Total, Cumulative	14	27	44	72	109	144	176	201

EPI ARTICLES IN THE WER BY MAJOR SUBJECT, BY YEAR AND ISSUE NUMBER: 1985-1988

Major Subject	1985	1986	1987	1988	Total
PROGRAMME ASPECTS:					
- Acceleration	-	36,37,48,49	5,24,51,52	6	8
- Description & Planning of the Programme	22,51	-	-	51	6
- GAG Reports	3	3	3	3	8
- Global and Regional	34	-	33	14	11
- Status Reports					
- Coverage surveys	27,47	42	10,18,25,29	29	47
- Country Programme Reviews and Development Reports	2,8,16,33,45	4,11,30,41,43	13,16,34,38,43,45	16,21,25,43	43
- Disease Impact	19	7,19,20,24,29,33	-	18,30	23
- Cold Chain	-	6,40	-	9,26	11
- Public Participation	-	-	-	-	4
- Training	-	-	-	-	2
- Cost Issues	25	47	14,20	-	11
- Other Operational	-	-	46	-	7
Issues					
EPIDEMIOLOGICAL ASPECTS:					
- of Diphtheria	-	21	-	-	3
- of Pertussis	-	23	21	-	2
- of Tetanus	29,46,49	14,16,45	7,35,41,44,47	10,34	22
- of Measles	11,13,14,21	12,22,25,44,46	10,19	22	21
- of Poliomyelitis	10	-	-	4,22,33,38,43	27
- of Tuberculosis	-	-	-	-	-
- General	41	-	-	12	3
VACCINES:					
- Diphtheria	-	-	-	-	1
- Tetanus	-	-	50	40	9
- Pertussis	39	10	-	-	4
- Measles	-	-	4	-	8
- Polio	-	-	-	-	7
- BCG	-	28	-	50	3
- General (including vaccine stability)	18,37	-	-	46	13
- Contraindications	31	17,35	9,30,39,40,42	37,45	17
Total, by year	26	34	33	27	
Total, Cumulative	227	261	294	321	321